Brief: Cure Pharmaceutical Expands U.S. DEA Approval To Manufacture Pharmaceuticals Using Whole Cannabis Plant
12/03/2019 11:37
March 12 (Reuters) - Cure Pharmaceutical Holding Corp
CURR.PK :
* CURE PHARMACEUTICAL EXPANDS U.S. DEA APPROVAL TO
MANUFACTURE
PHARMACEUTICALS USING WHOLE CANNABIS PLANT
* CURE PHARMACEUTICAL - BROADENED U.S. DEA LICENSE AS
AUTHORIZED
MANUFACTURER OF SCHEDULE 1 SUBSTANCES TO INCLUDE CANNABIS PLANT
EXTRACTS & SYNTHETIC CBD
Source text for Eikon: ID:nGNX4B46hJ
Further company coverage: CURR.PK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Avenir Wellness Solutions
See all newsBrief: Cure Pharmaceutical Reports Q2 2022 Results
Brief: Cure Pharmaceutical Announces Rob Davidson As New Chairman Of The Board And Appointment Of Rob Costantino As Member Of The Board And Audit Committee Chairman
Brief: Cure Pharmaceutical Holding Q1 Revenue $1.5 Million
Brief: CURE Pharmaceutical Augments Its Existing U.S. DEA License
Brief: Cure Pharmaceutical Receives FDA Approval For Its IND Application For Curefilm Blue